1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Local therapy for oligoprogression in NSCLC patients being treated with osimertinib
    Meeting Abstract

    Wang, C.; Yu, H.; Rusch, V. W.; Rimner, A.; Wu, A. J.
    International Journal of Radiation Oncology, Biology, Physics (2019)

    Fulltext@MSK | Save
  • Indirect treatment comparison of venetoclax plus rituximab with B-cell receptor inhibitors in patients with relapsed/refractory chronic lymphocytic leukaemia
    Meeting Abstract

    Mato, A.; Follows, G.; Sail, K.; Diakite, I.; Nicoloso, D.; Dietz, B.; Maher, J.; Alexiou, D.; Chirikov, V.
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Durability of response to venetoclax (VEN) in patients with CLL relapsed/refractory to ibrutinib and/or idelalisib
    Meeting Abstract

    Byrd, J.; Wierda, W.; Davids, M.; Choi, M.; Furman, R.; Mato, A.; Zhou, L.; Verdugo, M.; Potluri, J.; Coutre, S.
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Improving sepsis protocol compliance with smartphone sepsis alerts
    Meeting Abstract

    Zimmermann, M.; Chung, Y.; Garcia, J.; Tayban, K.; Fleming, C.; Connor, M.
    Critical Care Nurse (2019)

    Fulltext@MSK | Save
  • Efficacy of mogamulizumab by prior systemic therapy in patients with previously treated cutaneous T-cell lymphoma: Post hoc analysis from the phase 3 MAVORIC study
    Meeting Abstract

    Scarisbrick, J.; Zinzani, P. L.; Horwitz, S.; Kim, Y. H.; Moskowitz, A. J.; Porcu, P.; Leoni, M.; Dwyer, K.; Sun, W.; Nikonova, E.; more...
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Overall responses and survival in RCC on pegilodecakin with anti-PD-1
    Meeting Abstract

    Naing, A.; Infante, J. R.; Wong, D. J.; Korn, W. M.; Aljumaily, R.; Papadopoulos, K. P.; Autio, K. A.; Pant, S.; Bauer, T. M.; Drakaki, A.; more...
    European Journal of Cancer (2019)

    Fulltext@MSK | Save
  • Nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous haematopoietic cell transplantation: Extended follow-up of the phase 2 multi-cohort CheckMate 205 study
    Meeting Abstract

    Collins, G.; Armand, P.; Engert, A.; Younes, A.; Lee, H. J.; Santoro, A.; Zinzani, P. L.; Timmerman, J.; Ramchandren, R.; Cohen, J.; more...
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • DASFREE: An 18-month update of dasatinib discontinuation in patients with chronic myeloid leukemia in chronic phase and deep molecular response
    Meeting Abstract

    Shah, N. P.; García-Gutiérrez, V.; Jiménez-Velasco, A.; Larson, S.; Saussele, S.; Rea, D.; Mahon, F. X.; Levy, M. Y.; Gómez-Casare, M. T.; Pane, F.; more...
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Updated results from a phase Ib/II study in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G)
    Meeting Abstract

    McMillan, A.; Sehn, L.; Herrera, A.; Matasar, M.; Kamdar, M.; Assouline, S.; Hertzberg, M.; Kim, T. M.; Kim, W. S.; Ozcan, M.; more...
    British Journal of Haematology (2019)

    Fulltext@MSK | Save
  • Modelling kidney function recovery after nephrectomy in at-risk patients
    Meeting Abstract

    Silagy, A.; Mano, R.; Kashani, M.; Dinatale, R.; Blum, K.; Marcon, J.; Reznik, E.; Coleman, J.; Hakimi, A.; Russo, P.
    BJU International (2019)

    Fulltext@MSK | Save